To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Friday

Read the full 345 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE